Biocardia, inc. announces board changes, effective october 1, 2019

On september 25, 2019, pursuant to shareholder requests for nominees to be placed on the board of directors of biocardia, inc., the board accepted offers to resign from each of thomas quertermous, m.d. and allan r. tessler and appointed jim allen and andrew blank to fill these vacancies, effective october 1, 2019. neither dr. quertermous' nor mr. tessler's decision to resign was due to any disagreement with the company, including with respect to any matter relating to the company's operations, policies or practices. mr. allen will serve as a class ii director, with a term expiring at the company's 2021 annual meeting of stockholders. the board has named mr. allen to serve on the nominating and corporate governance committee of the board, effective october 1, 2019. mr. blank will serve as a class ii director, with a term expiring at the company's 2021 annual meeting of stockholders. the board has name mr. blank to serve on the compensation committee and the audit committee of the board, effective october 1, 2019.
BCDA Ratings Summary
BCDA Quant Ranking